INVO Fertility Inc (IVF)
INVO Fertility, Inc. is a healthcare company listed on NASDAQ under the ticker IVF. The company focuses on the fertility market and provides assisted reproductive technology care to patients. Its operations are organized across Fertility Clinic Services, the INVOcell Device, and Therapeutics. INVO Fertility offers the INVOcell Device, a medical device designed to enable fertilization and early embryo development to occur in vivo within the woman’s body, and it also operates fertility clinics, including INVO Centers. In addition, the company is developing NY-303, a GPC3 x NKp46 bifunctional antibody in a Phase I/II monotherapy trial for hepatocellular carcinoma, as well as NY-500, an AI-optimized bifunctional antibody. Formerly known as NAYA Biosciences, Inc., the company adopted the INVO Fertility name in April 2025 and is based in Sarasota, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IVF
|
$1.27
|
20.6% Upside
|
Undervalued
|
$20 1,804.8% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-0.2x
|
0.1x
|
0.3x
|
1.857 M
|
1.356 M
|
63.8%
|
99.9%
|
-8.8
|
—
|
48.4%
|
